Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 175 of 198 entries
View as:

Clinical Study on the Safety of Double and a Half Layered Esophagojejunal Anastomosis in Curative Gastrectomy

Phase: N/A Priority: Normal
NCT ID: NCT05282563 Org: User:
Start: 07/01/21 End: 06/01/24 Due: 06/01/25

Camrelizumab Combined With FOLFOX Neoadjuvant Therapy for Resectable Gastric and Gastroesophageal Junctional Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03939962 Org: User:
Start: 07/24/19 End: 05/30/24 Due: 05/30/25

Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT03383237 Org: User:
Start: 11/29/17 End: 11/30/19 Due: 11/30/20

Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03540303 Org: User:
Start: 04/12/18 End: 04/30/20 Due: 04/30/21

Efficacy of Pyrotinib Plus Capecitabine in HER2-positive MBC With Active Brain Metastases That Have Failed ADCs

Phase: N/A Priority: Normal
NCT ID: NCT06475443 Org: User:
Start: 06/15/24 End: 01/31/27 Due: 01/31/28

L218CAR19 in Patients With Relapsed/Refractory B-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT06478381 Org: User:
Start: 06/01/24 End: 06/30/26 Due: 06/30/27

Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05176080 Org: User:
Start: 12/08/21 End: 07/03/24 Due: 07/03/25

A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG

Phase: N/A Priority: Normal
NCT ID: NCT06774222 Org: User:
Start: 09/12/23 End: 12/31/26 Due: 12/31/27

A Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT06788197 Org: User:
Start: 03/31/25 End: 03/31/29 Due: 03/31/30

Comparison of TP and TAC Regimens in Neoadjuvant Treatment of TNBC

Phase: N/A Priority: Normal
NCT ID: NCT04664972 Org: User:
Start: 11/23/18 End: 11/26/22 Due: 11/26/23

PD-1 Inhibitor Sintilimab Combined With Capecitabine for Adjuvant Treatment After Radical Resection of Cholangiocarcinoma.

Phase: N/A Priority: Normal
NCT ID: NCT05207735 Org: User:
Start: 01/31/22 End: 12/31/24 Due: 12/31/25

Anrotinib Hydrochloride Combined With Adriamycin for Neoadjuvant Treatment of High-grade Soft Tissue Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT05747521 Org: User:
Start: 04/29/21 End: 09/30/24 Due: 09/30/25

Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type

Phase: N/A Priority: Normal
NCT ID: NCT03963193 Org: User:
Start: 06/01/19 End: 06/01/21 Due: 06/01/22

PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT05083208 Org: User:
Start: 02/20/22 End: 02/08/25 Due: 02/08/26

Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride Capsule

Phase: N/A Priority: Normal
NCT ID: NCT04223583 Org: User:
Start: 06/26/19 End: 04/30/21 Due: 04/30/22

Apatinib Plus SHR1210 in Advanced Mucosal Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT03986515 Org: User:
Start: 06/04/19 End: 05/31/22 Due: 05/31/23

The Maintenance Treatment of "ITIVA" in AML Patients

Phase: N/A Priority: Normal
NCT ID: NCT06256627 Org: User:
Start: 07/11/23 End: 05/01/27 Due: 05/01/28

RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT05923541 Org: User:
Start: 06/26/23 End: 08/31/24 Due: 08/31/25

Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation

Phase: N/A Priority: Normal
NCT ID: NCT02737774 Org: User:
Start: 04/13/16 End: 06/01/21 Due: 06/01/22

Mechanistic Study on the Diagnosis of Esophageal Cancer Lymph Node Metastasis Using Spectral CT, Multimodal MRI, FAPI PET-CT, Pathology, and AI Evaluation System

Phase: N/A Priority: Normal
NCT ID: NCT06818214 Org: User:
Start: 02/28/25 End: 12/31/30 Due: 12/31/31

Nab-P+Cb+PD1 Inhibitors Combined/not Combined with Bevacizumab As Neoadjuvant Therapy for Early TNBC

Phase: N/A Priority: Normal
NCT ID: NCT06817525 Org: User:
Start: 11/06/24 End: 11/06/25 Due: 11/06/26

CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03881761 Org: User:
Start: 02/01/19 End: 01/31/22 Due: 01/31/23

Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04067037 Org: User:
Start: 08/26/19 End: 12/31/26 Due: 12/31/27

PD1 Antibody Combined With mFOLFOX6 Neoadjuvant Therapy for Advanced Resectable Metastatic Colon Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06335147 Org: User:
Start: 04/01/24 End: 01/31/26 Due: 01/31/27

Long-term Follow-up of Anxiety and Depression in Patients With Malignant Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05596344 Org: User:
Start: 05/20/23 End: 11/30/32 Due: 11/30/33